Retinoblastoma protein expression predicts response to bacillus Calmette-Guérin immunotherapy in patients with T1G3 bladder cancer

• Published in: Urologic oncology 2010-05, Vol.28 (3), p.285-289
• Main Authors: Cormio, Luigi, M.D., Ph.D, Tolve, Isabella, Ph.D, Annese, Pasquale, M.D, Saracino, Alberto, M.D, Zamparese, Rosanna, M.D, Sanguedolce, Francesca, M.D., Ph.D, Bufo, Pantaleo, M.D., Ph.D, Battaglia, Michele, M.D, Selvaggi, Francesco Paolo, M.D, Carrieri, Giuseppe, M.D
• Format: Article
• Language: English
• Subjects: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - immunology; BCG Vaccine - administration & dosage; BCG Vaccine - immunology; Biological and medical sciences; Biomarkers, Tumor - analysis; Bladder cancer; Disease-Free Survival; Gene Expression Profiling; Humans; Immunohistochemistry; Immunotherapy; Kaplan-Meier Estimate; Medical sciences; Middle Aged; Neoplasm Staging; Nephrology. Urinary tract diseases; Prognosis; Retinoblastoma protein; Retinoblastoma Protein - biosynthesis; T1G3; Treatment Outcome; Tumors; Tumors of the urinary system; Urinary Bladder Neoplasms - metabolism; Urinary Bladder Neoplasms - pathology; Urinary Bladder Neoplasms - therapy; Urinary tract. Prostate gland; Urology
• ISSN: 1078-1439; 1873-2496
• DOI: 10.1016/j.urolonc.2008.08.003

Abstract Objectives Bacillus Calmette-Guérin (BCG) immunotherapy is regarded as the current treatment of choice for stage T1 grade 3 (T1G3) bladder cancer (BC), though its efficacy is limited by high recurrence and progression rate. Identification of molecular prognosticators that might be helpful in discriminating between responders and nonresponders to BCG treatment is therefore of major clinical importance; thus we focused on the cell-cycle related retinoblastoma protein (pRB), which had been already investigated in bladder cancer. The goal of our study was specifically to address whether its expression predicts the outcomes of BCG treatment for patients with T1G3 disease. Materials and Methods To address this issue, paraffin-embedded specimens of 27 patients having undergone transurethral resection of T1G3 BC and intravesical instillations of BCG (induction + 1 year maintenance) were immunostained with pRB monoclonal antibody. Patients in whom the bladder muscle was not clearly visible, and healthy, as well as patients with TaG3 tumors or with concomitant carcinoma in situ were excluded. Mean follow-up was 60 months (range 15–135). Results Thirteen tumors showed normal (1% to 50% labeling index) while 14 showed altered pRB expression, consisting of no expression (0% labeling index) in six and overexpression (>50% labeling index) in eight. Recurrence occurred in 10 (37%) patients and mean time to recurrence was 22.8 months (range 6–48). Recurrence rate was 57% in patients with altered and 15% in those with normal pRB expression, with a statistically significant difference in disease-free survival ( P = 0.037). Progression occurred in five (18.5%) patients and mean time to progression was 24 months (range 6–48). Progression rate was 36% in patients with altered and 0% in patients with normal pRB expression, with a statistically significant difference in progression-free survival ( P = 0.018). Conclusions In this homogeneous population of T1G3 bladder tumors, altered pRB expression predicted recurrence and progression after BCG treatment. These findings outline the potential role of pRB immunostaining in predicting T1G3 BC response to BCG immunotherapy.